R151.6 Antibody

What is R151.6 and what is its functional significance in research?

R151.6 refers to a C. elegans protein that functions as the homologue of the yeast Der1p protein. R151.6 plays a crucial role in the Endoplasmic Reticulum-Associated Degradation (ERAD) system, which is responsible for the degradation of malfolded soluble proteins. Research has demonstrated that R151.6 function is conserved from lower to higher eukaryotes, making it an important model for studying protein quality control mechanisms . When overexpressed, C. elegans R151.6 can partially rescue the conditional lethality of Dire1 Dder1 double mutant yeast strains and restore CPY* degradation in Dder1 strains to approximately 18% in 90 minutes, confirming its functional orthology to Der1p .

How are antibodies against R151.6 typically generated for research applications?

Antibodies against proteins like R151.6 are commonly generated through epitope-specific immunization strategies. The process typically involves:

• Identification of unique peptide sequences within the target protein

• Chemical synthesis of these peptide regions

• Conjugation to carrier proteins (such as keyhole limpet hemocyanine)

• Immunization of host animals (commonly rabbits for polyclonal antibodies)

• Affinity purification using epitope-specific immunogen chromatography

This approach, similar to that used for generating the Der1p antibodies described in the literature, typically yields antibodies with >95% purity as determined by SDS-PAGE analysis . For R151.6-specific antibodies, selecting peptide regions with minimal homology to related proteins is critical to ensure specificity.

What applications are R151.6 antibodies most commonly used for?

R151.6 antibodies are primarily utilized in fundamental research applications investigating protein degradation pathways and ER quality control mechanisms. Key applications include:

• Western blotting for protein expression analysis

• Immunohistochemistry (IHC) for localization studies

• Co-immunoprecipitation for protein interaction studies

• Pulse-chase analysis to study protein degradation kinetics

For optimal results in immunohistochemical applications, researchers typically use antibody concentrations of 10 μg/ml in appropriate diluent solutions when incubating overnight at 4°C, similar to protocols used for other protein-specific antibodies .

How should researchers validate the specificity of R151.6 antibodies before experimental use?

Validating antibody specificity is critical for reliable experimental outcomes. A comprehensive validation approach should include:

• Western blot analysis: Comparing wild-type expression with knockout/knockdown samples

• Cross-reactivity testing: Testing against related proteins to confirm specificity

• Peptide competition assays: Pre-incubating antibody with immunizing peptide should abolish signal

• Multiple antibody comparison: Using antibodies targeting different epitopes of R151.6

• Recombinant protein controls: Using purified R151.6 protein as positive control

For R151.6 antibody validation, researchers should demonstrate binding to the native protein from C. elegans lysates and confirm specificity by showing reduced or absent signal in R151.6 mutant strains. Similar to approaches used for testing other protein-specific antibodies, ELISA and Western blotting are effective validation methods .

What controls should be included when using R151.6 antibodies in immunohistochemistry?

When conducting immunohistochemistry with R151.6 antibodies, include these essential controls:

When developing fluorescent immunohistochemistry protocols, researchers should consider dual-labeling approaches using different markers. For example, the pericellular matrix can be visualized using anti-heparan sulfate proteoglycan antibodies with Alexa-Fluor-488 labeled secondary antibodies (green fluorescence), while R151.6 localization can be revealed using Cy5.5-labeled antibodies (red fluorescence) .

What are the optimal conditions for using R151.6 antibodies in Western blotting?

For Western blotting applications with R151.6 antibodies, consider these methodological guidelines:

• Sample preparation: Extract proteins using denaturing conditions (e.g., buffer containing 1% SDS, 2% Triton X-100, 10 mM EDTA)

• Protein loading: 10-20 μg total protein per lane is typically sufficient

• Transfer conditions: For R151.6 (~22 kDa size range), semi-dry transfer at 15V for 30 minutes or wet transfer at 100V for 1 hour

• Blocking solution: 5% non-fat dry milk or 3% BSA in TBST for 1 hour at room temperature

• Primary antibody dilution: Typically 1:500-1:2000, incubated overnight at 4°C

• Secondary antibody: Anti-rabbit HRP conjugate at 1:1000-1:5000 dilution for 1 hour at room temperature

• Detection method: Enhanced chemiluminescence (ECL) with exposure times adjusted based on signal strength

For optimal results, researchers should determine the linear dynamic range of their antibodies by performing titration experiments with different concentrations of both sample and antibody .

How can researchers optimize immunoprecipitation protocols using R151.6 antibodies?

Effective immunoprecipitation of R151.6 requires careful optimization of several parameters:

• Lysis buffer selection: Use non-denaturing buffers (e.g., 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40) with protease inhibitors

• Pre-clearing step: Incubate lysate with protein A/G beads for 1 hour to reduce non-specific binding

• Antibody amount: Typically 2-5 μg antibody per 500 μg of total protein

• Incubation conditions: Overnight at 4°C with gentle rotation

• Wash stringency: Multiple washes with decreasing salt concentrations to remove non-specific interactions

• Elution method: Gentle elution with acidic glycine buffer (pH 2.5) or more completely with SDS sample buffer

• Controls: Include mock IP (no antibody) and irrelevant antibody controls

For co-immunoprecipitation studies investigating R151.6 interaction partners, researchers should consider using crosslinking reagents like DSP (dithiobis(succinimidyl propionate)) to stabilize transient protein interactions before cell lysis .

How can researchers utilize R151.6 antibodies to study protein degradation kinetics?

Investigating R151.6's role in protein degradation pathways requires sophisticated experimental approaches:

• Pulse-chase analysis:

  • Pulse-label cells with 35S-methionine/cysteine for 5-10 minutes

  • Chase with excess unlabeled amino acids

  • Collect samples at various timepoints (0, 15, 30, 60, 90 min)

  • Immunoprecipitate R151.6 and its substrate proteins

  • Analyze by SDS-PAGE and autoradiography to determine degradation rates

• Cycloheximide chase assays:

  • Treat cells with cycloheximide to inhibit protein synthesis

  • Harvest cells at different timepoints

  • Analyze R151.6 and substrate protein levels by Western blotting

  • Calculate half-life based on protein abundance decay

This methodology has been successfully applied to analyze degradation of CPY* in yeast strains expressing C. elegans R151.6, showing partial restoration of degradation (approximately 18% in 90 minutes) compared to controls .

What approaches can be used to investigate R151.6's role in the ERAD pathway?

To comprehensively study R151.6's function in ERAD, researchers can employ these advanced techniques:

• Genetic interaction studies:

  • Create double mutants with other ERAD components

  • Assess phenotypic consequences (growth defects, UPR induction)

  • Measure degradation rates of model ERAD substrates

• Proteomic analysis of R151.6 interactome:

  • Perform immunoprecipitation with R151.6 antibodies

  • Identify binding partners through mass spectrometry

  • Validate interactions with co-immunoprecipitation and proximity ligation assays

• Functional assays:

  • Measure UPR activation using reporters (e.g., Hac1 splicing)

  • Assess ERAD substrate accumulation

  • Quantify ER stress through chaperone induction

These approaches can build upon findings that C. elegans R151.6 functionally complements Der1p in yeast, rescuing conditional lethality of Dire1 Dder1 double mutants and partially restoring CPY* degradation in Dder1 strains .

What are common issues when working with R151.6 antibodies and how can they be resolved?

Researchers may encounter several challenges when working with R151.6 antibodies:

For optimal results when performing immunostaining with R151.6 antibodies, researchers should perform antigen retrieval and block endogenous peroxidase activity with 3% hydrogen peroxide, similar to protocols used for other antibodies in immunohistochemistry applications .

How should researchers quantify and interpret R151.6 expression data from Western blots and immunohistochemistry?

Accurate quantification of R151.6 expression requires careful methodological approaches:

• Western blot quantification:

  • Use standard curves with purified recombinant protein

  • Ensure signal is in linear dynamic range

  • Normalize to appropriate loading controls (e.g., GAPDH, actin)

  • Use digital imaging software with background subtraction

  • Average results from at least three independent experiments

• Immunohistochemistry quantification:

  • Establish scoring system (e.g., H-score, Allred score)

  • Use digital image analysis with consistent thresholds

  • Assess multiple fields per sample (minimum 5-10)

  • Include positive and negative controls on same slide

  • Conduct blind scoring by multiple observers

When interpreting R151.6 expression data, researchers should consider cellular localization patterns, as these may provide insights into functional states. Similar to other ERAD components, R151.6 is expected to primarily localize to the ER membrane, and altered localization may indicate dysregulation of the ERAD pathway .

How might R151.6 antibodies be applied in investigating disease mechanisms?

R151.6 antibodies offer opportunities to explore disease mechanisms related to protein quality control:

• Neurodegenerative diseases:

  • Investigate R151.6 expression/function in models of Alzheimer's, Parkinson's, and ALS

  • Assess correlation between R151.6 dysfunction and protein aggregation

  • Examine potential therapeutic approaches targeting ERAD enhancement

• Cancer research:

  • Study R151.6 expression in different cancer types

  • Explore connections between ERAD dysfunction and tumor progression

  • Investigate potential of R151.6 as a biomarker or therapeutic target

• Inflammatory conditions:

  • Examine R151.6 role in ER stress-induced inflammation

  • Investigate potential applications in targeting delivery of anti-inflammatory cytokines

  • Develop novel therapeutic strategies similar to those explored for anti-inflammatory cytokines in arthritic joints

Understanding how R151.6 functions in different disease contexts may provide insights into pathogenesis and reveal novel therapeutic targets.

What emerging technologies might enhance R151.6 antibody applications in research?

Several cutting-edge technologies show promise for expanding R151.6 antibody applications:

• Super-resolution microscopy:

  • Achieve nanometer-scale resolution of R151.6 localization

  • Study co-localization with other ERAD components

  • Visualize dynamic interactions during protein degradation

• Single-cell proteomics:

  • Analyze R151.6 expression at single-cell level

  • Identify cell-to-cell variability in ERAD function

  • Correlate with other cellular parameters

• Engineered antibody fragments:

  • Develop smaller antibody formats (scFv, nanobodies) against R151.6

  • Improve tissue penetration and spatial resolution

  • Enable new applications such as intrabody expression

• Antibody-based proximity labeling:

  • Use R151.6 antibodies conjugated to enzymes like APEX2 or BioID

  • Map protein interaction networks in living cells

  • Identify transient interactions during ERAD

Similar to approaches used for creating peptide-centric chimeric antigen receptors (PC-CARs) for targeting intracellular oncoproteins , researchers might develop novel R151.6-targeting molecules for research or therapeutic applications.